AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 96 filers reported holding AVADEL PHARMACEUTICALS PLC in Q1 2023. The put-call ratio across all filers is 0.32 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $188,686 | -37.3% | 18,319 | +0.4% | 0.00% | – |
| Q2 2023 | $300,760 | +79.9% | 18,250 | 0.0% | 0.00% | – |
| Q1 2023 | $167,170 | +27.9% | 18,250 | 0.0% | 0.00% | – |
| Q4 2022 | $130,670 | +1206.7% | 18,250 | +808.0% | 0.00% | – |
| Q3 2022 | $10,000 | +233.3% | 2,010 | +518.5% | 0.00% | – |
| Q4 2021 | $3,000 | +200.0% | 325 | -10.7% | 0.00% | – |
| Q3 2019 | $1,000 | -94.4% | 364 | -97.1% | 0.00% | – |
| Q1 2019 | $18,000 | -43.8% | 12,500 | 0.0% | 0.00% | – |
| Q4 2018 | $32,000 | -41.8% | 12,500 | 0.0% | 0.00% | – |
| Q3 2018 | $55,000 | -28.6% | 12,500 | 0.0% | 0.00% | – |
| Q2 2018 | $77,000 | -15.4% | 12,500 | 0.0% | 0.00% | – |
| Q1 2018 | $91,000 | -11.7% | 12,500 | 0.0% | 0.00% | – |
| Q4 2017 | $103,000 | -21.4% | 12,500 | 0.0% | 0.00% | – |
| Q3 2017 | $131,000 | -5.1% | 12,500 | 0.0% | 0.00% | – |
| Q2 2017 | $138,000 | +14.0% | 12,500 | 0.0% | 0.00% | – |
| Q1 2017 | $121,000 | – | 12,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,498,838 | $22,889,355 | 11.72% |
| Knoll Capital Management, LLC | 500,000 | $4,580,000 | 7.06% |
| GENDELL JEFFREY L | 5,301,914 | $48,565,532 | 4.55% |
| COWEN AND COMPANY, LLC | 3,732,778 | $34,192,246 | 4.02% |
| Tri Locum Partners LP | 1,327,097 | $12,156,209 | 3.70% |
| Samsara BioCapital, LLC | 1,409,409 | $12,910,186 | 2.67% |
| Altium Capital Management LP | 500,000 | $4,580,000 | 2.54% |
| Vivo Capital, LLC | 3,761,438 | $34,454,772 | 2.39% |
| RTW INVESTMENTS, LP | 5,741,939 | $52,596,161 | 1.10% |
| Knott David M Jr | 291,113 | $2,667 | 1.05% |